AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16930863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 106
Study 14871462 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g oral moist snuff
Number of subjects: 20
Study 14871462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11495073 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (PI)
Number of subjects: 42
Study 11495073 — intervention group
Group type: COMPARATOR
Intervention: Routine surgical care (RC)
Number of subjects: 42
Study 9137797 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF treatment in TP-positive tumours
Number of subjects: 328
Study 9137797 — intervention group
Group type: COMPARATOR
Intervention: Non-treated patients with TP-positive tumours
Number of subjects: 328
Study 7547544 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 0
Study 2908103 — intervention group
Group type: EXPERIMENTAL
Intervention: Human calcitonin
Number of subjects: 0
Study 2908103 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 30755119 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention Nail System (PNS)
Number of subjects: 72
Study 30755119 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 72
Study 27872156 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP <120 mmHg
Number of subjects: 1441
Study 27872156 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP <70 mmHg
Number of subjects: 1441
Study 25523190 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vitamin D therapy
Number of subjects: 73
Study 25523190 — intervention group
Group type: COMPARATOR
Intervention: Stoss vitamin D therapy
Number of subjects: 73
Study 23318104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba dry extract
Number of subjects: 120
Study 23318104 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐lipoic acid plus vitamin C
Number of subjects: 120
Study 23318104 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine chlorhydrate plus vitamin E
Number of subjects: 120
Study 23318104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20589925 — intervention group
Group type: EXPERIMENTAL
Intervention: S. officinalis aroma
Number of subjects: 135
Study 20589925 — intervention group
Group type: EXPERIMENTAL
Intervention: S. lavandulaefolia aroma
Number of subjects: 135
Study 20589925 — intervention group
Group type: COMPARATOR
Intervention: No aroma (control)
Number of subjects: 135
Study 18816361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention DVD featuring a White female communicator
Number of subjects: 167
Study 18816361 — intervention group
Group type: COMPARATOR
Intervention: Control DVD featuring 2 Black female communicators
Number of subjects: 167
Study 17285994 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-Bone cement used to repair palate tabular damage
Number of subjects: 40
Study 12888639 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal tube feeding (12-h schedule)
Number of subjects: 6
Study 12888639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal tube feeding (12-h schedule)
Number of subjects: 6
Study 12888639 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h tube feeding
Number of subjects: 6
Study 12888639 — intervention group
Group type: COMPARATOR
Intervention: Placebo feeding (<0.4 MJ/d)
Number of subjects: 6
Study 11138755 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulations of the distinctness construct
Number of subjects: 0
Study 11138755 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-mutability as a contextual variable
Number of subjects: 0
Study 11138755 — intervention group
Group type: EXPERIMENTAL
Intervention: Social comparisons on self-evaluative judgments and behavioral predictions
Number of subjects: 0
Study 11138755 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood measures
Number of subjects: 0
Study 11138755 — intervention group
Group type: EXPERIMENTAL
Intervention: Importance ratings of the focal comparison dimension
Number of subjects: 0
Study 9174681 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg esuprone
Number of subjects: 16
Study 9174681 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg moclobemide
Number of subjects: 16
Study 9174681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1415368 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alpha (Cilag)
Number of subjects: 50
Study 1415368 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-beta (Boehringer)
Number of subjects: 50
Study 6367452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine (300 mg every six hours)
Number of subjects: 479
Study 6367452 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 479
Study 6367452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine tablets (300 mg three times a day and at bedtime)
Number of subjects: 479
Study 6367452 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly antacids (Mylanta II liquid 30 ml every hour)
Number of subjects: 479
Study 6367452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine plus hourly antacids
Number of subjects: 479
Study 6367452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 479
Study 30811630 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 2g of nanorap formulation (50mg lidocaine + 50mg prilocaine)
Number of subjects: 120
Study 30811630 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control formulation)
Number of subjects: 120
Study 30811630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanorap formulation
Number of subjects: 120
Study 29599348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed and carboplatin (PC)
Number of subjects: 222
Study 29599348 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and carboplatin (GC)
Number of subjects: 222
Study 27077267 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-needle arthrocentesis (Shepard cannula)
Number of subjects: 56
Study 27077267 — intervention group
Group type: COMPARATOR
Intervention: Double-needle arthrocentesis
Number of subjects: 56
Study 25631504 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole sustained-release film combined with minocycline hydrochloride
Number of subjects: 138
Study 25631504 — intervention group
Group type: COMPARATOR
Intervention: Minocycline hydrochloride
Number of subjects: 138
Study 22775467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 820 nm; continuous wave; output power: 50 mW; exposure duration: 5 sec; energy dose: 0.25 J; energy density: 7.96 J/cm(2) for each shot
Number of subjects: 19
Study 22775467 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (no laser treatment)
Number of subjects: 19
Study 19879750 — intervention group
Group type: EXPERIMENTAL
Intervention: E120 (epirubicin 120 mg/m²)
Number of subjects: 411
Study 19879750 — intervention group
Group type: COMPARATOR
Intervention: EC-CMF (epirubicin 90 mg/m² plus cyclophosphamide 600 mg/m² followed by CMF)
Number of subjects: 411
Study 19879750 — intervention group
Group type: EXPERIMENTAL
Intervention: E120
Number of subjects: 411
Study 19879750 — intervention group
Group type: COMPARATOR
Intervention: EC-CMF
Number of subjects: 411
Study 18517036 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol (GBX) 15 mg
Number of subjects: 41
Study 18517036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 16029679 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% niacinamide applied twice daily for 12 weeks
Number of subjects: 50
Study 16029679 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 12 weeks
Number of subjects: 50
Study 11812810 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminder intervention
Number of subjects: 143
Study 11812810 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone reminder)
Number of subjects: 143
Study 10412676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster schedule
Number of subjects: 63
Study 10412676 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional schedule
Number of subjects: 63
Study 10412676 — intervention group
Group type: COMPARATOR
Intervention: No immunotherapy
Number of subjects: 63
Study 7598088 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (Stomach, Hunger, Shen Men points) with diet and exercise program
Number of subjects: 19
Study 7598088 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (Stomach, Hunger points)
Number of subjects: 19
Study 7598088 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 19
Study 7598088 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie diet
Number of subjects: 19
Study 7598088 — intervention group
Group type: COMPARATOR
Intervention: Placebo ear points stimulation
Number of subjects: 19
Study 1805138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Number of subjects: 6
Study 1805138 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 6
Study 1805138 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin with clavulanic acid
Number of subjects: 6
Study 1805138 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid combination
Number of subjects: 6
Study 6339961 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (intensive courses of methotrexate with vincristine and prednisone reinductions and administration of cyclophosphamide)
Number of subjects: 88
Study 6339961 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (courses of methotrexate alternated with courses of 6‐mercaptopurine during consolidation and intensification therapy)
Number of subjects: 88
Study 6339961 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 0276/A (similar to regimen B but with L‐asparaginase and prolonged therapy duration)
Number of subjects: 88
Study 6339961 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 88
Study 6339961 — intervention group
Group type: COMPARATOR
Intervention: Combination of methotrexate and 6‐mercaptopurine
Number of subjects: 88
Study 31462863 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink N (Group VN)
Number of subjects: 45
Study 31462863 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilink N (Group MN)
Number of subjects: 45
Study 31462863 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilink Speed (Group MS)
Number of subjects: 45
Study 30390895 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day of EPA‐enriched oral nutrition supplementation (ONS)
Number of subjects: 50
Study 30390895 — intervention group
Group type: COMPARATOR
Intervention: EPA‐free ONS of similar energy (control group)
Number of subjects: 50
Study 26811060 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask (LM)
Number of subjects: 68
Study 26811060 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Intubation (ETI)
Number of subjects: 68
Study 24534289 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐Lynch suture
Number of subjects: 43
Study 22971879 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing desk
Number of subjects: 20
Study 22971879 — intervention group
Group type: COMPARATOR
Intervention: Sitting desk
Number of subjects: 20
Study 20408345 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual latex extract
Number of subjects: 30
Study 20408345 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 17223657 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) 20 mg once daily for 24 weeks
Number of subjects: 15
Study 17078441 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (penetrating needling, scalp acupuncture, strong/electric needling on body points)
Number of subjects: 98
Study 15220599 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (InflammEnz, Enzymes, Inc., Parkville, Mo.) - four capsules per day for 7 days
Number of subjects: 26
Study 15220599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 10910797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive adaptation training
Number of subjects: 45
Study 10910797 — intervention group
Group type: COMPARATOR
Intervention: Standard medication follow-up plus a condition designed to control for therapist time and provide environmental changes unrelated to cognitive deficits
Number of subjects: 45
Study 10910797 — intervention group
Group type: COMPARATOR
Intervention: Standard medication follow-up only
Number of subjects: 45
Study 8835112 — intervention group
Group type: EXPERIMENTAL
Intervention: ZVD (500 mg daily) + rG‐CSF (10 micrograms/Kg/biweekly) + Epo (50 IU/Kg/biweekly)
Number of subjects: 20
Study 8835112 — intervention group
Group type: COMPARATOR
Intervention: ZVD (500 mg/day) alone
Number of subjects: 20
Study 1279214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg terazosin
Number of subjects: 285
Study 1279214 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg terazosin
Number of subjects: 285
Study 1279214 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg terazosin
Number of subjects: 285
Study 1279214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 3901170 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (200 mg)
Number of subjects: 23
Study 3901170 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg)
Number of subjects: 23
Study 3901170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30778710 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue cleaning intervention
Number of subjects: 95
Study 30778710 — intervention group
Group type: COMPARATOR
Intervention: No tongue cleaning intervention (Control)
Number of subjects: 95
Study 28731003 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 intravenously every 3 weeks for three cycles followed by Pemetrexed consolidation every 3 weeks for 4 cycles.
Number of subjects: 598
Study 28731003 — intervention group
Group type: COMPARATOR
Intervention: Arm B: Standard therapy with Etoposide 50 mg/m2 and Cisplatin 50 mg/m2 intravenously every 4 weeks for two cycles followed by two cycles of consolidation platinum-based doublet chemotherapy.
Number of subjects: 598
Study 28731003 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 intravenously.
Number of subjects: 598
Study 28731003 — intervention group
Group type: COMPARATOR
Intervention: Arm B: Standard therapy with Etoposide and Cisplatin.
Number of subjects: 598
Study 28731003 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: Pemetrexed and Cisplatin.
Number of subjects: 598
Study 28731003 — intervention group
Group type: COMPARATOR
Intervention: Arm B: Etoposide and Cisplatin.
Number of subjects: 598
Study 25111959 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 120 mg/m2
Number of subjects: 16
Study 23597114 — intervention group
Group type: EXPERIMENTAL
Intervention: DePuy ASR Hip Resurfacing System (RHA)
Number of subjects: 38
Study 23597114 — intervention group
Group type: COMPARATOR
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 38
Study 23597114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt ions
Number of subjects: 38
Study 23597114 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium ions
Number of subjects: 38
Study 21567350 — intervention group
Group type: EXPERIMENTAL
Intervention: High Aerobic Endurance Group (HEG)
Number of subjects: 30
Study 21567350 — intervention group
Group type: COMPARATOR
Intervention: Low Aerobic Endurance Group (LEG)
Number of subjects: 30
Study 18489687 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational intervention programme with two visits to a nurse specialized in COPD care.
Number of subjects: 52
Study 18489687 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group).
Number of subjects: 52
Study 16645967 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate 7.5 mg/week + cyclosporine 2.5 mg/kg/day)
Number of subjects: 160
Study 16645967 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (methotrexate + placebo-cyclosporine)
Number of subjects: 160
Study 16645967 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate + intraarticular glucocorticoid)
Number of subjects: 160
Study 16645967 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate + cyclosporine)
Number of subjects: 160
Study 14521003 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention (generic and individualized videos)
Number of subjects: 82
Study 14521003 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 82
Study 11200920 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention (15 individual sessions including counseling, relaxation, diabetes education, and cognitive strategies)
Number of subjects: 40
Study 11200920 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 8983088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 4 mg/day
Number of subjects: 10
Study 8983088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (CORT) 10 mg/h
Number of subjects: 10
Study 8983088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1457111 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (1.25 MAC for 15 minutes)
Number of subjects: 50
Study 1457111 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (1.6%)
Number of subjects: 50
Study 1457111 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.05, 0.1, or 0.15 mg/kg IV) with desflurane
Number of subjects: 50
Study 1457111 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (0.05, 0.1, or 0.15 mg/kg IV) with isoflurane
Number of subjects: 50
Study 6091501 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg in the morning (Group II)
Number of subjects: 150
Study 6091501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg (Group III)
Number of subjects: 150
Study 6091501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg and metoclopramide, 10 mg in the morning (Group IV)
Number of subjects: 150
Study 6091501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg at bedtime and in the morning (Group V)
Number of subjects: 150
Study 6091501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg at bedtime and in the morning and metoclopramide, 10 mg in the morning (Group VI)
Number of subjects: 150
Study 6091501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg in the morning (Group VII)
Number of subjects: 150
Study 6091501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg and metoclopramide, 10 mg in the morning (Group VIII)
Number of subjects: 150
Study 6091501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg at bedtime and in the morning (Group IX)
Number of subjects: 150
Study 6091501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg at bedtime and in the morning and metoclopramide, 10 mg in the morning (Group X)
Number of subjects: 150
Study 6091501 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 150
Study 30406847 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-focus endoscopy with narrow-band imaging (DF-NBI)
Number of subjects: 170
Study 30406847 — intervention group
Group type: COMPARATOR
Intervention: White light imaging (WLI)
Number of subjects: 170
Study 30055926 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% SCAM inclusion
Number of subjects: 6
Study 30055926 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% SCAM inclusion
Number of subjects: 6
Study 30055926 — intervention group
Group type: COMPARATOR
Intervention: 0% SCAM inclusion
Number of subjects: 6
Study 30055926 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAM diets
Number of subjects: 6
Study 30055926 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAM inclusion
Number of subjects: 6
Study 27267500 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavioral therapy (CBT‐E)
Number of subjects: 242
Study 27267500 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal psychodynamic therapy (FPT)
Number of subjects: 242
Study 27267500 — intervention group
Group type: COMPARATOR
Intervention: Optimized treatment as usual (TAU‐O)
Number of subjects: 242
Study 25127703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cationic emulsion (CE) - Cationorm
Number of subjects: 79
Study 25127703 — intervention group
Group type: COMPARATOR
Intervention: PVA-P - Refresh
Number of subjects: 79
Study 22581822 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 148
Study 22581822 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel
Number of subjects: 148
Study 19502285 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 5 u (first dose)
Number of subjects: 20
Study 19502285 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 5 u (second dose)
Number of subjects: 20
Study 17718902 — intervention group
Group type: EXPERIMENTAL
Intervention: Students informed about the benefits of changing answers; Outcome: changed answers significantly more often than those not informed.
Number of subjects: 79
Study 17718902 — intervention group
Group type: COMPARATOR
Intervention: Students not informed about the benefits of changing answers; Outcome: changed answers less often than those informed.
Number of subjects: 79
Study 15172774 — intervention group
Group type: EXPERIMENTAL
Intervention: amphotericin B plus flucytosine (100 mg/kg daily)
Number of subjects: 64
Study 15172774 — intervention group
Group type: COMPARATOR
Intervention: amphotericin B (0.7 mg/kg daily)
Number of subjects: 64
Study 15172774 — intervention group
Group type: COMPARATOR
Intervention: amphotericin B plus fluconazole (400 mg daily)
Number of subjects: 64
Study 15172774 — intervention group
Group type: COMPARATOR
Intervention: triple therapy with amphotericin B, flucytosine, and fluconazole
Number of subjects: 64
Study 11368133 — intervention group
Group type: EXPERIMENTAL
Intervention: Video information prior to attendance
Number of subjects: 0